OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic
Tirosh Shapira, I. Abrrey Monreal, Sébastien P. Dion, et al.
Nature (2022) Vol. 605, Iss. 7909, pp. 340-348
Open Access | Times Cited: 171
Tirosh Shapira, I. Abrrey Monreal, Sébastien P. Dion, et al.
Nature (2022) Vol. 605, Iss. 7909, pp. 340-348
Open Access | Times Cited: 171
Showing 1-25 of 171 citing articles:
Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants
Cong Sun, Chu Xie, Guo‐Long Bu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 113
Cong Sun, Chu Xie, Guo‐Long Bu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 113
Small molecules in the treatment of COVID-19
Sibei Lei, Xiaohua Chen, Jieping Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 78
Sibei Lei, Xiaohua Chen, Jieping Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 78
Oral antiviral treatments for COVID-19: opportunities and challenges
Laila Rahmah, Sunny O. Abarikwu, Amanuel Godana Arero, et al.
Pharmacological Reports (2022) Vol. 74, Iss. 6, pp. 1255-1278
Open Access | Times Cited: 70
Laila Rahmah, Sunny O. Abarikwu, Amanuel Godana Arero, et al.
Pharmacological Reports (2022) Vol. 74, Iss. 6, pp. 1255-1278
Open Access | Times Cited: 70
TMPRSS2 Is Essential for SARS-CoV-2 Beta and Omicron Infection
Kristin Metzdorf, Henning Jacobsen, Marina C. Greweling‐Pils, et al.
Viruses (2023) Vol. 15, Iss. 2, pp. 271-271
Open Access | Times Cited: 43
Kristin Metzdorf, Henning Jacobsen, Marina C. Greweling‐Pils, et al.
Viruses (2023) Vol. 15, Iss. 2, pp. 271-271
Open Access | Times Cited: 43
Human coronavirus HKU1 recognition of the TMPRSS2 host receptor
Matthew McCallum, Young‐Jun Park, Cameron Stewart, et al.
Cell (2024) Vol. 187, Iss. 16, pp. 4231-4245.e13
Open Access | Times Cited: 16
Matthew McCallum, Young‐Jun Park, Cameron Stewart, et al.
Cell (2024) Vol. 187, Iss. 16, pp. 4231-4245.e13
Open Access | Times Cited: 16
SARS-CoV-2 Drug Resistance and Therapeutic Approaches
Sania Batool, Santosh Chokkakula, Ju Hwan Jeong, et al.
Heliyon (2025) Vol. 11, Iss. 2, pp. e41980-e41980
Open Access | Times Cited: 3
Sania Batool, Santosh Chokkakula, Ju Hwan Jeong, et al.
Heliyon (2025) Vol. 11, Iss. 2, pp. e41980-e41980
Open Access | Times Cited: 3
An intranasal ASO therapeutic targeting SARS-CoV-2
Chi Zhu, Justin Y. Lee, Jia Z. Woo, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 61
Chi Zhu, Justin Y. Lee, Jia Z. Woo, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 61
Aryl hydrocarbon receptor is a proviral host factor and a candidate pan-SARS-CoV-2 therapeutic target
Jiandong Shi, Tingfu Du, Junbin Wang, et al.
Science Advances (2023) Vol. 9, Iss. 22
Open Access | Times Cited: 27
Jiandong Shi, Tingfu Du, Junbin Wang, et al.
Science Advances (2023) Vol. 9, Iss. 22
Open Access | Times Cited: 27
SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models
Anna Z. Mykytyn, Tim I. Breugem, Maarten H. Geurts, et al.
Journal of Virology (2023) Vol. 97, Iss. 8
Open Access | Times Cited: 27
Anna Z. Mykytyn, Tim I. Breugem, Maarten H. Geurts, et al.
Journal of Virology (2023) Vol. 97, Iss. 8
Open Access | Times Cited: 27
Inhalation of ACE2-expressing lung exosomes provides prophylactic protection against SARS-CoV-2
Zhenzhen Wang, Shiqi Hu, Kristen D. Popowski, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 13
Zhenzhen Wang, Shiqi Hu, Kristen D. Popowski, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 13
Adaptive immune cells are necessary for SARS-CoV-2–induced pathology
Brian Imbiakha, Julie Sahler, David W. Buchholz, et al.
Science Advances (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 8
Brian Imbiakha, Julie Sahler, David W. Buchholz, et al.
Science Advances (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 8
Neutralizing antibodies to block viral entry and for identification of entry inhibitors
Ee-Hong Tam, Peng Yu, Megan Xin Yan Cheah, et al.
Antiviral Research (2024) Vol. 224, pp. 105834-105834
Closed Access | Times Cited: 8
Ee-Hong Tam, Peng Yu, Megan Xin Yan Cheah, et al.
Antiviral Research (2024) Vol. 224, pp. 105834-105834
Closed Access | Times Cited: 8
Human coronavirus HKU1 recognition of the TMPRSS2 host receptor
Matthew McCallum, Young‐Jun Park, Cameron Stewart, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 7
Matthew McCallum, Young‐Jun Park, Cameron Stewart, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 7
Glycan-directed SARS-CoV-2 inhibition by leek extract and lectins with insights into the mode-of-action of Concanavalin A
Maja Klevanski, Heeyoung Kim, Mike Heilemann, et al.
Antiviral Research (2024) Vol. 225, pp. 105856-105856
Open Access | Times Cited: 7
Maja Klevanski, Heeyoung Kim, Mike Heilemann, et al.
Antiviral Research (2024) Vol. 225, pp. 105856-105856
Open Access | Times Cited: 7
Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2
Jessica Wagoner, Shawn Herring, Tien-Ying Hsiang, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 5
Open Access | Times Cited: 34
Jessica Wagoner, Shawn Herring, Tien-Ying Hsiang, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 5
Open Access | Times Cited: 34
PCIF1-mediated deposition of 5′-cap N 6 ,2′- O -dimethyladenosine in ACE2 and TMPRSS2 mRNA regulates susceptibility to SARS-CoV-2 infection
Lingling Wang, Shaobo Wang, Lujing Wu, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 5
Open Access | Times Cited: 20
Lingling Wang, Shaobo Wang, Lujing Wu, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 5
Open Access | Times Cited: 20
Targeting SARS-CoV-2 entry processes: The promising potential and future of host-targeted small-molecule inhibitors
Aijia Wu, Kunyu Shi, Jiaxing Wang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 263, pp. 115923-115923
Closed Access | Times Cited: 17
Aijia Wu, Kunyu Shi, Jiaxing Wang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 263, pp. 115923-115923
Closed Access | Times Cited: 17
Functionalized Fullerene for Inhibition of SARS‐CoV‐2 Variants
Taylor M. Page, Chuanxiong Nie, Lenard Neander, et al.
Small (2023) Vol. 19, Iss. 15
Open Access | Times Cited: 16
Taylor M. Page, Chuanxiong Nie, Lenard Neander, et al.
Small (2023) Vol. 19, Iss. 15
Open Access | Times Cited: 16
Danshensu inhibits SARS-CoV-2 by targeting its main protease as a specific covalent inhibitor and discovery of bifunctional compounds eliciting antiviral and anti-inflammatory activity
Ruyu Wang, Xuwen Chen, Hongtao Li, et al.
International Journal of Biological Macromolecules (2023) Vol. 257, pp. 128623-128623
Closed Access | Times Cited: 15
Ruyu Wang, Xuwen Chen, Hongtao Li, et al.
International Journal of Biological Macromolecules (2023) Vol. 257, pp. 128623-128623
Closed Access | Times Cited: 15
Neutrophil proteases are protective against SARS-CoV-2 by degrading the spike protein and dampening virus-mediated inflammation
Nathan Gf Leborgne, Christelle Devisme, Nedim Kozarac, et al.
JCI Insight (2024) Vol. 9, Iss. 7
Open Access | Times Cited: 6
Nathan Gf Leborgne, Christelle Devisme, Nedim Kozarac, et al.
JCI Insight (2024) Vol. 9, Iss. 7
Open Access | Times Cited: 6
ACE2 acts as a novel regulator of TMPRSS2-catalyzed proteolytic activation of influenza A virus in airway cells
Miriam Ruth Heindl, Anna-Lena Rupp, Marie Schwerdtner, et al.
Journal of Virology (2024) Vol. 98, Iss. 4
Open Access | Times Cited: 5
Miriam Ruth Heindl, Anna-Lena Rupp, Marie Schwerdtner, et al.
Journal of Virology (2024) Vol. 98, Iss. 4
Open Access | Times Cited: 5
Progress in SARS-CoV-2, diagnostic and clinical treatment of COVID-19
Yang Li, Si-Ming Lu, Jia-Long Wang, et al.
Heliyon (2024) Vol. 10, Iss. 12, pp. e33179-e33179
Open Access | Times Cited: 5
Yang Li, Si-Ming Lu, Jia-Long Wang, et al.
Heliyon (2024) Vol. 10, Iss. 12, pp. e33179-e33179
Open Access | Times Cited: 5
TMPRSS2 as a Key Player in Viral Pathogenesis: Influenza and Coronaviruses
Gilmara Barros de Lima, Everton Nencioni, Fábio Thimoteo, et al.
Biomolecules (2025) Vol. 15, Iss. 1, pp. 75-75
Open Access
Gilmara Barros de Lima, Everton Nencioni, Fábio Thimoteo, et al.
Biomolecules (2025) Vol. 15, Iss. 1, pp. 75-75
Open Access
Dissecting the Binding Affinity of Anti-SARS-CoV-2 Compounds to Human Transmembrane Protease, Serine 2: A Computational Study
Yongwei Shi, Jianxin Shen, Tao Yan, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 587-587
Open Access
Yongwei Shi, Jianxin Shen, Tao Yan, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 587-587
Open Access
Trypstatin as a Novel TMPRSS2 Inhibitor with Broad-Spectrum Efficacy Against Corona and Influenza Viruses
Jan Lawrenz, Lukas Wettstein, Armando Rodríguez, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Jan Lawrenz, Lukas Wettstein, Armando Rodríguez, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
